Nath Bio-Genes (India) Ltd (NATHBIOGEN) — Board Meeting | 1 September 2026

Nath Bio-Genes (India) Ltd announced its 33rd AGM scheduled for 24 September 2026 via video conferencing, with e-voting from 21-23 September 2026. Shareholders will vote on adoption of FY2025-26 standalone and consolidated financial statements, declaration of a final dividend of ₹2 per equity share (face value ₹10), re-appointment of Director Jeevanlata Kagliwal, re-appointment of Independent Director Hitesh Rajnikant Purohit for a second term (2027-2032), and revision of Managing Director Satish Kagliwal's remuneration to ₹1.44 crore per annum. Record date for dividend eligibility is 11 September 2026, with payment by 29 September 2026. Shareholding as of 31 March 2026 stood at 19,00,40,000 equity shares, with 98.54% dematerialized. The company reported FY26 revenue of ₹4,316 million, EBITDA of [amount context mismatch] million (12% margin), and PAT of [amount context mismatch] million, reflecting 19% YoY growth. EPS rose to [amount context mismatch], supported by five years of compounding. The Board highlighted robust pipelines in cotton, paddy, maize, vegetables, and non-crop segments, with focus on R&D, distribution expansion, farmer engagement, and international growth, particularly in Uzbekistan where it holds 90% equity in a subsidiary. Risks include regulatory tightening on GM/hybrid seeds, Draft Seeds Bill 2025, monsoon variability, and input supply disruptions from China. Mitigation includes diversified portfolios, R&D investments, and inventory management. The company maintains a robust governance framework with five board committees, a whistleblower policy, and compliance with SEBI and Ind AS standards.